Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Genomic Testing Cooperative Lca is navigating 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are assigned to 2 distinct examiners and the specified art units. Such a distribution indicates that the company's current patent applications are being evaluated by different technical groups within the patent office. The involvement of multiple art units suggests a range of genomic or pharmaceutical technologies under review. This requires the applicant to maintain a flexible prosecution strategy that can adapt to the specific requirements of each unit within the Biotechnology & Pharmaceuticals sector.
SMITH, JENNIFER JOY is the busiest examiner, currently managing 1 pending office action. With a total of 2 pending office actions, the workload is shared between the examiners. This requires the applicant to address the specific concerns of different art units. The lack of a single point of concentration means that prosecution strategies may need to be customized for each individual examiner. Because SMITH, JENNIFER JOY is responsible for 1 pending office action, the applicant can dedicate specific attention to this case without it being overshadowed by a larger volume of work. Managing the pending office actions across separate examiners allows for parallel progress.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SMITH, JENNIFER JOY | 1 | — | — |
| POHNERT, STEVEN C | 1 | 12.4% | +18.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17850756 | METHODS FOR FORECASTING CLINICAL COURSE OF DIFFUSE LARGE B-CELL LYMPHOMA USING RNA-BASED BIOMARKERS AND MACHINE LEARNING ALGORITHMS | SMITH, JENNIFER JOY | 9d |
| 17720624 | Compositions and Methods for Targeted NGS Sequencing of cfRNA and cfTNA | POHNERT, STEVEN C | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17720624 | Compositions and Methods for Targeted NGS Sequencing of cfRNA and cfTNA | POHNERT, STEVEN C | — |
| Art Unit | Apps |
|---|---|
| 1685 | 1 |
| 1683 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17850756 | METHODS FOR FORECASTING CLINICAL COURSE OF DIFFUSE LARGE B-CELL LYMPHOMA USING RNA-BASED BIOMARKERS AND MACHINE LEARNING ALGORITHMS | SMITH, JENNIFER JOY | 1685 | §101§103§112 | Final Rejection | 9d | Pending | Jun 27, 2022 |
| 17720624 | Compositions and Methods for Targeted NGS Sequencing of cfRNA and cfTNA | POHNERT, STEVEN C | 1683 | §101§103§112 | Final Rejection | — | Pending | Apr 14, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial